Session

IBD (Posters)

ULCERATIVE COLITIS: CHARACTERISTICS OF INTESTINAL MICROBIOTA IN RUSSIAN POPULATION
ULCERATIVE COLITIS: CHARACTERISTICS OF INTESTINAL MICROBIOTA IN RUSSIAN POPULATION

EFFICACY OF USTEKINUMAB AT THE END OF MAINTENANCE IN ULCERATIVE COLITIS PATIENTS RECEIVING 6 MG/ KG INDUCTION POSOLOGY. DATA FROM UNIFI TRIAL
EFFICACY OF USTEKINUMAB AT THE END OF MAINTENANCE IN ULCERATIVE COLITIS PATIENTS RECEIVING 6 MG/ KG INDUCTION POSOLOGY. DATA FROM UNIFI TRIAL

DIFFUSION-WEIGHTED MAGNETIC RESONANCE ENTEROCOLONOGRAPHY AND CDEIS IN ASSESSING CROHN_S DISEASE ACTIVITY
DIFFUSION-WEIGHTED MAGNETIC RESONANCE ENTEROCOLONOGRAPHY AND CDEIS IN ASSESSING CROHN_S DISEASE ACTIVITY

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

NON-SUPPRESSIVE FOXP3+ T HELPER CELLS, BUT NOT REGULATORY T CELLS, ARE INCREASED IN COLLAGENOUS COLITIS MUCOSA
NON-SUPPRESSIVE FOXP3+ T HELPER CELLS, BUT NOT REGULATORY T CELLS, ARE INCREASED IN COLLAGENOUS COLITIS MUCOSA

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY
SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

GENETIC TESTING OF HLA-DQA1-HLA-DRB1 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GENETIC TESTING OF HLA-DQA1-HLA-DRB1 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

EVALUATION OF INTEREST AND KEY FEATURES OF A HEALTH CARE APP TO ASSIST IN THE MANAGEMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AMONGST CLINICAL TRIAL SITES IN THE UNITED STATES
EVALUATION OF INTEREST AND KEY FEATURES OF A HEALTH CARE APP TO ASSIST IN THE MANAGEMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AMONGST CLINICAL TRIAL SITES IN THE UNITED STATES

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY
FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY

IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

REAL WORLD USE OF THE IBD DISK TOOL IN UNSELECTED COHORTS OF OUTPATIENTS
REAL WORLD USE OF THE IBD DISK TOOL IN UNSELECTED COHORTS OF OUTPATIENTS

GASTROINTESTINAL ULTRASOUND PERFORMED ON ADMISSION PREDICTS THE NEED FOR INPATIENT INFLIXIMAB THERAPY IN HOSPITALISED ULCERATIVE COLITIS PATIENTS
GASTROINTESTINAL ULTRASOUND PERFORMED ON ADMISSION PREDICTS THE NEED FOR INPATIENT INFLIXIMAB THERAPY IN HOSPITALISED ULCERATIVE COLITIS PATIENTS

WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS
WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS

EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN
EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN

RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS
RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS

REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS
REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS

VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS
VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL
EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL

Item 61 - 80 / 558
1 2 3
4
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28